Concurrent gemcitabine and 3D radiotherapy in patients with stage III unresectable non-small cell lung cancer
2014
Background
Stage III unresectable non-small cell lung cancer (NSCLC) is preferably treated with concurrent schedules of chemoradiotherapy, but none is clearly superior Gemcitabine is a radiosensitizing cytotoxic drug that has been studied in phase 1 and 2 studies in this setting. The aim of this study was to describe outcome and toxicity of low-dose weekly gemcitabine combined with concurrent 3-dimensional conformal radiotherapy (3D-CRT).
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
24
References
5
Citations
NaN
KQI